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Pediatric in-hospital cardiac arrest is a devas-
tating condition with the average annual incidence 
of 15,200 cases in the United States [1]. The sur-
vival rate after hospital discharge remains poor 
(~55%) [2], although it shows an increasing trend 
in the last decade [3]. In the pediatric population, 
around 10% of patients have initial shockable 
rhythms (ventricular fibrillation or pulseless ven-
tricular tachycardia) following cardiac arrest, and 
15% of patients develop them during resuscitation. 
The rate of shockable rhythms varies depending on 
the patient age and is lowest for infants, followed 
by children and adolescents [4]. Early defibrillation 
and high-quality cardiopulmonary resuscitation are 
the core of treatment for cardiac arrests caused by 
shockable rhythms, followed by administration of 
adrenaline and antiarrhythmic drugs [5].
Amiodaron and lidocaine are used in the treat-
ment of pediatric cardiac arrest with shockable 
rhythms refractory to defibrillation. Previously, 
amiodaron was recommended by the American 
Heart Association (AHA) Guidelines for Cardiopul-
monary Resuscitation and Emergency Cardiovascu-
lar Care 2010: Pediatric Advanced Life Support [6], 
and by the European Resuscitation Council (ERC) 
2010: Pediatric Life Support Guidelines [7] as the 
preferred antiarrhythmic. Currently, both AHA 
2020 [8] and ERC 2021 Guidelines [5] state that 
amiodaron and lidocaine can be used interchange-
ably, depending on the physician’s preferences. 
However, data regarding the outcomes associated 
with amiodarone and lidocaine administration in 
pediatric cardiac arrest are very limited. Therefore, 
this study is a systematic review and meta-analysis 
to determine the efficacy of amiodarone and lido-
caine in pediatric cardiac arrest.
This present review and meta-analysis were 
performed following the Preferred Reporting 
Items for Systematic reviews and Meta-analysis 
(PRISMA) guidelines. The search of data included 
the Embase, Medline and the Cochrane from the da-
tabases’ inception to April 15, 2021. Studies included 
in this meta-analysis met the following PICOS crite-
ria: (1) Participants: patients < 18 years of age with 
cardiac arrest due to any cause; (2) Intervention: 
amiodarone treatment; (3) Comparison: treatment 
with lidocaine; (4) Outcomes: detailed information 
for survival; (5) Study design: randomized controlled 
trials, observational trials comparing lidocaine and 
amiodarone in pediatric resuscitation. Studies were 
excluded if they were reviews, guidelines or articles 
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Following identification and selection of the 
relevant studies for the present meta-analysis 
and removal of duplicates and nonrelevant trials, 
two studies were included in the analysis [9, 10]. 
Both studies focused on in-hospital cardiac arrest 
(IHCA).
Results of the pooled analysis of IHCA out-
comes is presented in Table 1. In the full cohort, 
the use of lidocaine in pediatric resuscitation was 
associated with a higher incidence of return of 
spontaneous circulation (71.4% vs. 59.1%, re-
spectively; odds ratio [OR] 1.96; 95% confidence 
interval [CI] 1.39–2.77; p < 0.001), survival to 24 h 
(54.0% vs. 39.7%; OR 1.94; 95% CI 1.39–2.69; 
p < 0.001) and survival to hospital discharge 
(32.2% vs. 23.4%; OR 1.68; 95% CI 1.16–2.44; 
p = 0.006), compared to amiodaron. There were 
no differences regarding favorable neurological 
outcome at hospital discharge in patients who re-
ceived lidocaine and amiodarone (21.0% vs. 21.3%, 
respectively; OR 0.98; 95% CI 0.57–1.68; p = 
= 0.95). In the propensity-score matched cohort 
data (comparison of propensity-matched patients 
from the first study [9] and all patients from the sec-
ond study [10], no significant differences between 
the use of lidocaine and amiodarone were found in 
terms of all researched outcomes. 
In conclusion, despite better IHCA out-
comes associated with lidocaine in the full cohort 
analysis, analysis of the propensity-matched data 
showed no significant differences between the 
treatment arms. Although the small number of 
studies included in this meta-analysis and lack of 
access to individual patient data is a limitation, 
the meta-analysis herein, implies that results 
of previous studies comparing lidocaine and 
amiodarone in pediatric cardiac arrest should be 
interpreted which caution, as the observed differ-
ences might be due to substantial differences in 
patient baseline and clinical characteristics. Fur-
ther randomized controlled trials are warranted to 
establish which treatment strategy is associated 
with better outcomes.
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Table 1. Pooled analysis of pediatric cardiac arrest outcomes in patients treated with lidocaine and 
amiodarone.
Adverse event  
type




Events Heterogeneity  
between trials







OR 95% CI P-value I2 statistic
Full cohort data




1.96 1.39–2.77 0.45 0% < 0.001




1.94 1.39–2.69 0.82 0% < 0.001




1.68 1.16–2.44 0.99 0% 0.006






0.98 0.57–1.68 NA NA 0.95
Matched cohort data




1.51 0.64–3.55 0.04 76% 0.35




1.48 0.77–2.83 0.10 64% 0.24




1.31 0.84–2.05 0.27 16% 0.23






0.59 0.27–1.31 NA NA 0.19
CI — confidence interval; NA — not applicable, OR — odds ratio; ROSC — return of spontaneous circulation; SHD — survival to hospital dis-
charge
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